JASPER THERAPEUTICS INC (JSPR) Stock Price, Quote, News and Overview
NASDAQ:JSPR - Nasdaq - US4718712023 - Common Stock - Currency: USD
JSPR Quote, Performance and Key Statistics
JASPER THERAPEUTICS INC
NASDAQ:JSPR (2/5/2025, 9:42:40 AM)
6.36
+0.04 (+0.63%)
The current stock price of JSPR is 6.36 USD. In the past month the price decreased by -67.2%. In the past year, price decreased by -64.07%.
JSPR Latest News, Press Releases and Analysis
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7...
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
Webinar to be held Wednesday, January 8, 2025, at 8am EST...
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...
JSPR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.92 | 338.42B | ||
| AMGN | AMGEN INC | 15.3 | 163.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 951.98 | 125.03B | ||
| GILD | GILEAD SCIENCES INC | 22.35 | 123.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.89 | 79.70B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.92B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.15B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.40B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.6 | 15.86B |
Related stock screener links
About JSPR
Company Profile
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 45 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). The company also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Company Info
JASPER THERAPEUTICS INC
2200 Bridge Pkwy Suite #102
Redwood City CALIFORNIA US
CEO: Bala Venkataraman
Employees: 45
Company Website: https://www.jaspertherapeutics.com/
Investor Relations: https://ir.jaspertherapeutics.com/
Phone: 16505491400
JSPR FAQ
What is the stock price of JSPR?
The current stock price of JSPR is 6.36 USD.
What is the symbol for JASPER THERAPEUTICS INC stock?
The exchange symbol of JASPER THERAPEUTICS INC is JSPR and it is listed on the Nasdaq exchange.
On which exchange is JSPR stock listed?
JSPR stock is listed on the Nasdaq exchange.
Is JSPR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for JSPR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of JSPR.
Does JSPR stock pay dividends?
JSPR does not pay a dividend.
What is the Price/Earnings (PE) ratio of JSPR?
JSPR does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.74).
What is the Short Interest ratio of JSPR stock?
The outstanding short interest for JSPR is 21.71% of its float.
JSPR Technical Analysis
JSPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JSPR. No worries on liquidiy or solvency for JSPR as it has an excellent financial health rating, but there are worries on the profitability.
JSPR Financial Highlights
Over the last trailing twelve months JSPR reported a non-GAAP Earnings per Share(EPS) of -4.74. The EPS decreased by 42.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.9% | ||
| ROE | -75.92% | ||
| Debt/Equity | 0 |
JSPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to JSPR. The Buy consensus is the average rating of analysts ratings from 17 analysts.